Intellia Therapeutics is trading 5.21% lower at $11.93, with biotech-sector weakness the clearest context identified, though no clear sector-wide catalyst has been identified. - The supplied sector context shows XBI down 2.01%; it does not fully account for Intellia’s larger decline. - Intellia announced Jing L. Marantz as incoming chief medical officer on October 13, effective October 26; available reporting does not establish the appointment as the reason for the decline.